CCR1 blockade and myeloma bone disease

Blood

Volumn 120, Issue 7, 2012, Pages 1351-1352

  Sebag, Michael ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CCX721 PROTEIN; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE DISEASE; CELL SURVIVAL; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); DRUG BIOAVAILABILITY; HUMAN; MULTIPLE MYELOMA; NONHUMAN; NOTE; OSTEOCLAST; OSTEOLYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; STEM CELL; TUMOR VOLUME;

EID: 84865159589     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-06-434019     Document Type: Note

References (9)

1. Dairaghi DJ, Oyajobi BO, Gupta A, et al. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. Blood. 2012;120(7):1449-1457.
2. Raje N, Roodman GD. Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res. 2011;17(6):1278-1286.
3. Terpos E, Moulopoulos LA, Dimopoulos MA. Advances in imaging and the management of myeloma bone disease. J Clin Oncol. 2011;29(14):1907-1915.
4. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354(6):610-621. (Pubitemid 43209108)
5. Cao Y, Luetkens T, Kobold S, et al. The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients. Exp Hematol. 2010;38(10):860-867.
6. Masih-Khan E, Trudel S, Heise C, et al. MIP-1αlpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma. Blood. 2006;108(10):3465-3471.
7. Vallet S, Anderson KC. CCR1 as a target for multiple myeloma. Expert Opin Ther Targets. 2011;15(9):1037-1047.
8. Menu E, De Leenheer E, De Raeve H, et al. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clin Exp Metastasis. 2006;23(5-6):291-300.
9. Morgan GJ, Davies FE, Gregory WM, et al. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. Blood. 2012;119(23):5374-5383.